|Home Monitor for Congestive Heart Failure |
Accel is currently focusing on its first product:
pScreen-BNP™: the first not-implantable daily home test for the monitoring of
heart failure patients. BNP is a cardiac biomarker known for its
specificity and sensitivity in the diagnosis of Congestive Heart Failure (CHF).
Accel’s solution marks a paradigm shift in the management of
CHF and presents a nearly $3 Billion opportunity. It allows for the first time,
CHF patients to frequently monitor their level of heart distress, outside the
clinical setting, in the comfort of their home.
Accel’s solution enables patients and their physicians to
respond before physical symptoms occur, preventing otherwise frequent life
threatening events and costly reoccurring hospitalizations.
CHF affects over 5.7 million Americans resulting in 1.1
million hospitalizations annually and over 50% hospital re-admissions within one
year of hospitalization. Readmissions due to recurrent events are preventable
and treatable outside the hospital setting with early diagnosis. These
preventable and unnecessary readmissions contribute to $18 billion of the $39 billion burden of the disease.